Eastwood Bio-Medical Canada (TSXV:EBM) EBITDA: C$-0.18 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:EBM Eastwood Bio-Medical Canada Inc TSXV:EBM
25 GF Score
Price C$0.99
GF Value C$0.53
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Eastwood Bio-Medical Canada EBITDA?

Eastwood Bio-Medical Canada TSXV:EBM +1.02% 25 EBITDA is C$-0.18 Mil as of Apr. 2026. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Eastwood Bio-Medical Canada's EBITDA for the three months ended in Apr. 2026 was C$-0.05 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was C$-0.18 Mil.

During the past 3 years, the average EBITDA Growth Rate was -97.60% per year. During the past 5 years, the average EBITDA Growth Rate was 11.30% per year. During the past 10 years, the average EBITDA Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Eastwood Bio-Medical Canada was 60.80% per year. The lowest was -97.60% per year. And the median was -3.35% per year.

Eastwood Bio-Medical Canada's EBITDA per Share for the three months ended in Apr. 2026 was C$-0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Apr. 2026 was C$-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Eastwood Bio-Medical Canada was 18.30% per year. The lowest was -58.70% per year. And the median was 1.75% per year.

Eastwood Bio-Medical Canada  (TSXV:EBM) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Eastwood Bio-Medical Canada EBITDA Related Terms


Eastwood Bio-Medical Canada EBITDA Historical Data

* Premium members only.

The historical data trend for Eastwood Bio-Medical Canada's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eastwood Bio-Medical Canada EBITDA Chart

Eastwood Bio-Medical Canada Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.50 -0.03 -0.41 -0.33 -0.25

Eastwood Bio-Medical Canada Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.06 -0.04 -0.03 -0.05

TSXV:EBM vs VRTX, REGN, RVMD: EBITDA Comparison

For the Biotechnology subindustry, Eastwood Bio-Medical Canada's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eastwood Bio-Medical Canada EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Eastwood Bio-Medical Canada's EV-to-EBITDA falls into.


TSXV:EBM
25GF Score
Eastwood Bio-Medical Canada Inc TSXV:EBM
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Eastwood Bio-Medical Canada's EBITDA for the fiscal year that ended in Oct. 2025 is calculated as

Eastwood Bio-Medical Canada's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Oct. 2025, Eastwood Bio-Medical Canada's EBITDA was C$-0.25 Mil.

Eastwood Bio-Medical Canada's EBITDA for the quarter that ended in Apr. 2026 is calculated as

Eastwood Bio-Medical Canada's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Apr. 2026, Eastwood Bio-Medical Canada's EBITDA was C$-0.05 Mil.

EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of C$-0.18 Mil mean?
Eastwood Bio-Medical Canada (TSXV:EBM) has a EBITDA of C$-0.18 Mil as of Apr. 2026. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Eastwood Bio-Medical Canada.
Is Eastwood Bio-Medical Canada's EBITDA too high?
Eastwood Bio-Medical Canada's current EBITDA is C$-0.18 Mil. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's EBITDA compare to VRTX and REGN?
Eastwood Bio-Medical Canada's EBITDA of C$-0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Biotechnology company?
A good EBITDA depends on the Biotechnology industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Eastwood Bio-Medical Canada. Eastwood Bio-Medical Canada's current EBITDA is C$-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current EBITDA is C$-0.18 Mil. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current EBITDA is C$-0.18 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?

Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued. The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53. GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.

Key valuation signals for TSXV:EBM:

  • EBITDA: C$-0.18 Mil
  • GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
  • GF Score™: 25/100 with 4 warning signs

No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eastwood Bio-Medical Canada Business Description

Address 4871 Shell Road, Suite 1130, Richmond, BC, CAN, V6X 3Z6
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score

Get the complete analysis for TSXV:EBM

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.99
Price
C$0.53
GF Value